Conversely, data from FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) with evolocumab reported that rates of depressive disorders were 2.0% in each study group, events of major depression being more frequent in patients on placebo (14 events) than in those given evolocumab (5 events) [54, 55]. The gene discussed is PCSK9; the disease is major depressive disorder.